🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

32 results for “Cycle” Clear

  1. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  2. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  3. Zelenectide Pevedotin, BT8009, PEMBROLIZUMAB, AVELUMAB, CISPLATIN, CARBOPLATIN, GEMCITABINE

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  4. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  5. BT1718

    BICYCLE THERAPEUTICS

    Advanced Solid Tumours

    phase 2 small molecule completed

    1 trial

  6. BT8009, Zelenectide Pevedotin

    BICYCLE THERAPEUTICS

    NECTIN4 Amplified Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  7. BT8009, Zelenectide Pevedotin, PEMBROLIZUMAB

    BICYCLE THERAPEUTICS

    Nectin-4 Expressing Advanced Malignancies.

    phase 2 small molecule active

    1 trial

  8. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  9. Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  10. IW-1701

    Cyclerion Therapeutics

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  11. IW-1973

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  12. Matching Placebo

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  13. NIVOLUMAB, BT5528

    BICYCLE THERAPEUTICS

    Advanced Malignancies Associated with EphA2 Expression

    phase 2 small molecule active

    1 trial

  14. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Olinciguat

    Cyclerion Therapeutics

    Achalasia

    phase 2 small molecule terminated

    1 trial

  16. Zelenectide Pevedotin, BT8009

    BICYCLE THERAPEUTICS

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. 15NH4Cl, Sodium Chloride for injection, [13C]Sodium Acetate, CMP-CPS-001

    Camp4 Therapeutics Corp

    Urea cycle disorders (UCD)

    phase 1 small molecule active

    1 trial

  18. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  19. IW-1701

    Cyclerion Therapeutics

    Healthy

    phase 1 small molecule completed

    2 trials

  20. IW-1973

    Cyclerion Therapeutics

    Healthy

    phase 1 small molecule completed

    2 trials

  21. Olinciguat

    Cyclerion Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  22. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  23. Ritonavir for cycle1 and NORVIR for cycle 2

    The First People's Hospital of Lianyungang

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  24. [14C]-olinciguat

    Cyclerion Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources